Cantor Assumes Buy on Cerus Corporation (CERS), Sees 40% Upside for the Stock


In a research report sent to investors Thursday, Cantor analyst Bryan Brokmeier assumed coverage on shares of Cerus Corporation (NASDAQ:CERS), with a Buy rating and price target of $9.00, which represents a potential upside of 43% from where the stock is currently trading.

Brokmeier wrote, “CERS is a blood safety company with differentiated technology that reduces the risk of transfusion-transmitted infections, while saving hospitals money. Growth and profitability have struggled in recent years, but we believe accelerating adoption for platelets in the U.S., a potential 2H:17 CE Mark for red blood cells in Europe, and a recent federal grant to further the development of its U.S. red blood cell program position the company for double-digit growth for the next decade as it penetrates a $7.0B addressable market.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Bryan Brokmeier has a yearly average return of 1.1% and a 44% success rate. Brokmeier is ranked #1649 out of 4013 analysts.

Out of the 7 analysts polled by TipRanks, 6 rate Cerus stock a Buy, while 1 rates the stock a Hold. With a return potential of 36%, the stock’s consensus target price stands at $8.58.

 

The BioPortfolio is the only sure way to make profits trading biotech stocks. Learn more HERE and set up your top notch portfolio in seconds.

 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts